Alboun Samer M, Khreisat Eman, Alawneh Zaid E, Bani Hani Khaled M, Khreisat Rania F, Al-Mughrabi Mohammed A, Alshagoor Bara'ah E, Alfarajat Rabaa I, Doumi Madher A, Cycline Mino
Rehabilitation and Rheumatology, Jordanian Royal Medical Services, Amman, JOR.
Family Medicine, King Hussein Medical Center, Amman, JOR.
Cureus. 2024 May 7;16(5):e59830. doi: 10.7759/cureus.59830. eCollection 2024 May.
This study was aimed to determine the ideal thresholds for bone mineral densities in our tested Jordanian cohort to initiate bisphosphonate pharmacotherapeutics in order to establish a national protocol for prescribing bisphosphonates that is tailored to the local population, rather than relying on global T and Z scores standards.
This retrospective study analyzed the entire population of adult patients at Prince Rashid bin Al-Hussein Hospital Rehabilitation and Rheumatology Center between August and October 2023 for the purpose of screening, monitoring, diagnosing, and treating osteoporosis. The study included 328 clients suspected to have osteoporosis, selected based on criteria such as primary osteoporosis or potential secondary osteoporosis. The study used two fracture risk assessment tools (FRAX) dichotomized states: <3% (negative state) and ≥3% (positive state), as well as <20% (negative state) and ≥20% (positive state). Binary logistic regression analysis, receiver-operating characteristic, and sensitivity analysis tests were performed sequentially to analyze the performance of prognosticators and sensitivity indices to evaluate their sensitivity, specificity, and accuracy indexes.
The study involved 328 clients at a rehabilitation clinic, with 82.62% (271) females and 17.38% (57) males. The majority were aged between 60 and 69 years, with a slightly higher obesity rate in females. The study found that initiation of bisphosphonates in Jordanian cohorts with optimal bone mineral density thresholds of 0.775 g/cm may significantly reduce the risk of hip osteoporosis over 10 years, with sensitivity, specificity, and accuracy indexes of 78.6%, 88.46%, and 50.61%, respectively, with a performance utility of 0.896±0.026 (p-value<0.001), 95% CI (0.846-0.946).
Due to ethnicity differences, exploring regional or national specific bone mineral density thresholds for bisphosphonates initiation may be a better optional choice than adopting global T-score standards.
本研究旨在确定我们所测试的约旦队列中启动双膦酸盐药物治疗的理想骨密度阈值,以便制定一项针对当地人群的双膦酸盐处方国家方案,而不是依赖全球T值和Z值标准。
这项回顾性研究分析了2023年8月至10月期间拉希德·本·侯赛因王子医院康复与风湿病中心的所有成年患者,目的是筛查、监测、诊断和治疗骨质疏松症。该研究纳入了328名疑似患有骨质疏松症的患者,这些患者是根据原发性骨质疏松症或潜在继发性骨质疏松症等标准挑选出来的。该研究使用了两种骨折风险评估工具(FRAX)的二分状态:<3%(阴性状态)和≥3%(阳性状态),以及<20%(阴性状态)和≥20%(阳性状态)。依次进行二元逻辑回归分析、受试者工作特征分析和敏感性分析测试,以分析预测指标和敏感性指数的性能,评估其敏感性、特异性和准确性指标。
该研究涉及一家康复诊所的328名患者,其中女性占82.62%(271名),男性占17.38%(57名)。大多数患者年龄在60至69岁之间,女性肥胖率略高。研究发现,约旦队列中骨密度最佳阈值为0.775g/cm时启动双膦酸盐治疗,可能会在10年内显著降低髋部骨质疏松症的风险,敏感性、特异性和准确性指标分别为78.6%、88.46%和50.61%,性能效用为0.896±0.026(p值<0.001),95%置信区间(0.846 - 0.946)。
由于种族差异,探索双膦酸盐起始治疗的区域或国家特定骨密度阈值可能比采用全球T值标准是更好的选择。